Literature DB >> 7594040

Adverse consequences of high sympathetic nervous activity in the failing human heart.

D M Kaye1, J Lefkovits, G L Jennings, P Bergin, A Broughton, M D Esler.   

Abstract

OBJECTIVES: In view of previous experimental evidence relating sympathetic nervous overactivity in the heart to myocardial necrosis and ventricular arrhythmias, we prospectively examined the hypothesis that heightened cardiac sympathetic nervous activity is associated with an adverse outcome in patients with moderate to severe heart failure.
BACKGROUND: Despite recent therapeutic advances, patients with heart failure continue to have high mortality from progressive hemodynamic decompensation and lethal ventricular arrhythmias. It is believed that initially compensatory increases in sympathetic nervous system activity may ultimately be maladaptive, potentially contributing to subsequent adverse events.
METHODS: Sixty patients with moderate to severe heart failure (left ventricular ejection fraction 18.9 +/- 0.9% [mean +/- SE]) were studied prospectively. In addition to the compilation of a hemodynamic, biochemical and electrocardiographic profile for each patient, whole-body and cardiac sympathetic activity were determined by isotope dilution. The relation of these variables to outcome was determined by Cox proportional hazards analysis.
RESULTS: The mean follow-up period of the study group was 7 +/- 1 months (range 1 to 24) with a 12-month actuarial survival of 75%. Deaths (14 in all) were accounted for either by sudden death or progressive heart failure in equal numbers. The rate of release of norepinephrine from the heart was significantly higher in patients with heart failure than in healthy subjects (402 +/- 37 vs. 105 +/- 19 pmol/min, p < 0.01), although the values for heart failure ranged widely from normal to 10 times normal. By univariate Cox proportional hazards analysis, pulmonary capillary wedge pressure (p < 0.01), mean pulmonary artery pressure (p < 0.001), serum sodium levels (p < 0.01) and cardiac norepinephrine spill-over rate (p < 0.001) were identified as significant prognostic markers. In a multivariate analysis, cardiac norepinephrine spillover rate was identified as the most powerful prognostic marker (p = 0.0006) of those evaluated in this study.
CONCLUSIONS: These results suggest that activation of the sympathetic nervous system in patients with heart failure, specifically the cardiac sympathetic nerves, may contribute to the poor prognosis associated with severe heart failure. The data therefore provide a rationale for the use of drugs such as beta-adrenergic blocking agents in the management of patients with heart failure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594040     DOI: 10.1016/0735-1097(95)00332-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  149 in total

Review 1.  Heart Failure: Treatment strategies for heart failure: beta blockers andantiarrhythmics.

Authors:  A P Maggioni
Journal:  Heart       Date:  2001-01       Impact factor: 5.994

Review 2.  MIBG imaging.

Authors:  Amar D Patel; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2002 Jan-Feb       Impact factor: 5.952

3.  Augmented single-unit muscle sympathetic nerve activity in heart failure with chronic atrial fibrillation.

Authors:  Tatsunori Ikeda; Hisayoshi Murai; Shuichi Kaneko; Soichiro Usui; Daisuke Kobayashi; Manabu Nakano; Keiko Ikeda; Shin-Ichiro Takashima; Takeshi Kato; Masaki Okajima; Hiroshi Furusho; Masayuki Takamura
Journal:  J Physiol       Date:  2011-12-05       Impact factor: 5.182

4.  Impaired cardiac adrenergic innervation assessed by MIBG imaging as a predictor of treatment response in childhood dilated cardiomyopathy.

Authors:  P Acar; P Merlet; L Iserin; D Bonnet; D Sidi; A Syrota; J Kachaner
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

Review 5.  Emerging clinical applications in cardiovascular pharmacogenomics.

Authors:  Samir B Damani; Eric J Topol
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2010-08-20

Review 6.  Neurocardiology: therapeutic implications for cardiovascular disease.

Authors:  David S Goldstein
Journal:  Cardiovasc Ther       Date:  2010-11-25       Impact factor: 3.023

7.  Hyperphosphorylation of the cardiac ryanodine receptor at serine 2808 is not involved in cardiac dysfunction after myocardial infarction.

Authors:  Hongyu Zhang; Catherine A Makarewich; Hajime Kubo; Wei Wang; Jason M Duran; Ying Li; Remus M Berretta; Walter J Koch; Xiongwen Chen; Erhe Gao; Héctor H Valdivia; Steven R Houser
Journal:  Circ Res       Date:  2012-02-02       Impact factor: 17.367

8.  Extension of myocardial necrosis differently affects MIBG retention in heart failure caused by ischaemic heart disease or by dilated cardiomyopathy.

Authors:  Cecilia Marini; Assuero Giorgetti; Alessia Gimelli; Annette Kusch; Nadia Sereni; Antonio L'abbate; Paolo Marzullo; Gianmario Sambuceti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-03-04       Impact factor: 9.236

Review 9.  Cardiac metaiodobenzylguanidine imaging and heart failure.

Authors:  Tomoaki Nakata; Akiyoshi Hashimoto; Hirohito Sugawara
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 10.  Neural mechanisms and management of obesity-related hypertension.

Authors:  Murray D Esler; Nina Eikelis; Elisabeth Lambert; Nora Straznicky
Journal:  Curr Cardiol Rep       Date:  2008-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.